Rest-Of-Middle-East Preimplantation Genetic Testing Market Size, Share,Trends, Growth Analysis Report, 2030

Overview Request Sample Pages Request Customization Download PDF

You are viewing: Rest Of Middle East Preimplantation Genetic Testing Market analysis

Part of: Preimplantation Genetic Testing Market (Global)

The Rest Of Middle East Preimplantation Genetic Testing Market was valued at $0.63 Million in 2025 and projected to reach to $0.93 Million by 2030, representing a compound annual growth rate of 8.1%. The Rest Of Middle East preimplantation genetic testing market is positioned for steady growth as healthcare providers increasingly recognize the clinical and economic benefits of genetic screening.

Rest Of Middle East Preimplantation Genetic Testing Market (2025-2030) : Size and Share

CAGR of

USD Million

Rest Of Middle East Preimplantation Genetic Testing Market Trends and Insights

Rest Of Middle East represents an emerging segment within the broader Middle East region, where increasing awareness of genetic screening and reproductive health is driving adoption.
The region's growth trajectory reflects rising fertility clinic investments and growing patient demand for advanced diagnostic solutions in Rest Of Middle East. Rest Of Middle East's 8.1% compound annual growth rate demonstrates moderate but consistent market development through the forecast period.
The expansion in Rest Of Middle East is supported by improving healthcare infrastructure, rising disposable incomes, and greater accessibility to assisted reproductive technologies.
Rest Of Middle East continues to lag behind more developed markets, yet the region shows promising potential as healthcare providers expand genetic testing capabilities and regulatory frameworks evolve to support innovation in reproductive medicine..

Key Market Statistics

CAGR (2025-2030) 8.1% CAGR
Market Size, 2025 ~USD 0.63 Million
Forecast, 2030 ~USD 0.93 Million
Country Rest Of Middle East

Rest Of Middle East Preimplantation Genetic Testing Market Overview

Market Valuation Growth :

Rest Of Middle East PGT market valued at $0.63 million in 2025, expanding to $0.93 million by 2030, representing a compound annual growth rate of 8.1% over the forecast period.

Emerging Market Segment :

Rest Of Middle East represents an emerging segment within the broader Middle East region, characterized by increasing awareness of genetic screening technologies and growing emphasis on reproductive health management.

Regional Growth Drivers :

Steady expansion driven by rising adoption of preimplantation genetic testing, improved healthcare infrastructure, and growing patient education regarding genetic disorders and fertility optimization in Rest Of Middle East countries.

Comparative Growth Trajectory :

While Rest Of Middle East grows at 8.1% CAGR, the global market expands at 10.5% CAGR, indicating the region has significant catch-up potential as healthcare systems mature and accessibility improves.

Rest Of Middle East Preimplantation Genetic Testing Market Dynamics

Rising disposable incomes, improved fertility clinic infrastructure, and growing patient awareness about genetic disorders are key catalysts driving market expansion in the region.
Healthcare systems are gradually adopting advanced reproductive technologies, supported by evolving regulatory frameworks and increased investment in diagnostic capabilities. Looking ahead, Rest Of Middle East is expected to experience accelerated adoption as medical professionals receive enhanced training in PGT methodologies and patient accessibility improves.
The market will likely benefit from regional collaborations with leading fertility centers, growing medical tourism for reproductive services, and increasing government support for reproductive health initiatives.
By 2030, the market is projected to reach $0.93 million, reflecting the region's transition toward more sophisticated genetic testing protocols and personalized reproductive medicine approaches..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies

Polymerase Chain Reaction (PCR)
Reagents
Assay Kits
Bioinformatics
Flow Cytometry

Top Companies

Thermo Fisher Scientific Inc.
Illumina, Inc.
Agilent Technologies, Inc.
Qiagen N.V.
Danaher Corporation

Biotechnology

Top Technologies

Reagents
Polymerase Chain Reaction (PCR)
Stem Cells
Assay Kits
Flow Cytometers

Top Companies

Thermo Fisher Scientific Inc.
Merck KGaA
Danaher Corporation
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.

Key Takeaways

Rest Of Middle East PGT market valued at $0.63 million in 2025, expanding to $0.93 million by 2030 at 8.1% CAGR
Rest Of Middle East demonstrates emerging market characteristics with growing fertility clinic infrastructure and patient awareness
Rest Of Middle East growth driven by improving healthcare access, rising incomes, and expanding assisted reproductive technology adoption
Rest Of Middle East regulatory environment and healthcare investment trends position the region for sustained market development

Preimplantation Genetic Testing Market Report Scope

Report Metric	Details
Base Year	2025
Fastest Growing Segment	SINGLE GENE DISORDERS (Application)
Forecast Period	2025�2030
Growth Rate	CAGR of 10.5% from 2025 to 2030
Largest Segment	PREIMPLANTATION GENETIC SCREENING (Procedure Type)
Market Size Base Year (Billions)	~USD 0.69 (2025)
Revenue Forecast (Billions)	~USD 1.14 (2030)
Segments Covered	Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

Rest Of Middle East Preimplantation Genetic Testing Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product & Service

Instruments
Reagents & Consumables
Software & Services

By Procedure Type

Preimplantation Genetic Diagnosis
Preimplantation Genetic Screening

By Technology

Comparative Genomic Hybridization
Fluorescence In Situ Hybridization
Next-Generation Sequencing
Polymerase Chain Reaction
Single-Nucleotide Polymorphism

By Application

Aneuploidy
Gender Identification
Hla Typing
Single Gene Disorders
Structural Chromosomal Abnormalities
X-Linked Disorders

By Type

Deletions
Duplications
Inversions
Translocations

By Type Of Cycle

Fresh Donor
Fresh Non-Donor
Frozen Donor
Frozen Non-Donor

By End User

Diagnostic Laboratories
Fertility Clinics
Hospitals
Other End Users

Target Audience

Fertility Clinic Operators : Fertility centers and reproductive health providers in Rest Of Middle East need market data to justify PGT service investments, understand demand potential, and plan technology adoption roadmaps.
Diagnostic Equipment Manufacturers : Medical device and diagnostic companies require Rest Of Middle East-specific market intelligence to identify distribution opportunities, assess regional demand, and develop localized go-to-market strategies.
Healthcare Investors & PE Firms : Investment firms evaluating reproductive health opportunities in Rest Of Middle East need accurate market sizing and growth forecasts to assess investment returns and portfolio diversification potential.
Healthcare Policy Makers : Government health agencies and regulatory bodies in Rest Of Middle East require market data to inform healthcare policy, reimbursement frameworks, and infrastructure development for genetic testing services.
Market Research & Consulting Firms : Research organizations and consultants serving healthcare clients need Rest Of Middle East-specific PGT market data to support client advisory work, competitive analysis, and strategic planning engagements.

Key Companies in the Rest Of Middle East Preimplantation Genetic Testing Market

Company	HQ	Ownership	Strongest segments
CIMARON LABEL			Pressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
THERMO FISHER SCIENTIFIC INC.	United States	Public Company	Laboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
AGILENT TECHNOLOGIES, INC.	United States	Public Company	Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
REVVITY	United States	Public Company	Reagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
COOPERCOMPANIES	United States	Public Company	Spherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
ABBOTT	United States	Public Company	Diagnostic Products,Medical Devices,Nutritional Products,
TAKARA BIO INC.	Japan	Private Company	Research reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
VITROLIFE	Sweden	Public Company	IVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

CIMARON LABEL

Insufficient information provided to generate description.

THERMO FISHER SCIENTIFIC INC.

Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

AGILENT TECHNOLOGIES, INC.

Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

REVVITY

Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

COOPERCOMPANIES

CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

ABBOTT

Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

TAKARA BIO INC.

Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

VITROLIFE

Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

Reasons to Buy this Report

Emerging Market Entry Strategy : Gain critical insights into Rest Of Middle East's untapped PGT market potential with detailed valuation data, growth projections, and regional dynamics to inform market entry and expansion strategies.
Competitive Positioning Intelligence : Understand the competitive landscape specific to Rest Of Middle East, including market gaps, growth opportunities, and regional adoption patterns to differentiate your offerings and capture market share.
Investment Decision Support : Access comprehensive market sizing and CAGR analysis for Rest Of Middle East to support investment decisions, business case development, and resource allocation for reproductive health technology initiatives.
Regional Growth Forecasting : Leverage accurate 2025-2030 forecast data specific to Rest Of Middle East to plan product launches, partnerships, and capacity expansion aligned with projected market growth trajectories.
Stakeholder Alignment : Present data-driven market insights to investors, boards, and partners regarding Rest Of Middle East's emerging PGT segment to secure buy-in for regional development programs and strategic initiatives.

Frequently asked questions

What is the current market size of preimplantation genetic testing in Rest Of Middle East?

Rest Of Middle East's PGT market was valued at $0.63 million in 2025 and is expected to reach $0.93 million by 2030.

What is the projected growth rate for Rest Of Middle East's PGT market?

Rest Of Middle East's preimplantation genetic testing market is projected to grow at a compound annual growth rate of 8.1% from 2025 to 2030.

What factors are driving growth in Rest Of Middle East's PGT market?

Rest Of Middle East's market growth is driven by improving healthcare infrastructure, rising disposable incomes, increased patient awareness of genetic screening, and expanding fertility clinic capabilities.

How does Rest Of Middle East compare to the global PGT market?

Rest Of Middle East's 8.1% CAGR is slightly below the global average of 10.5%, reflecting the region's emerging market status and developing healthcare infrastructure.

What challenges does Rest Of Middle East face in PGT market adoption?

Rest Of Middle East faces challenges including limited regulatory frameworks, lower awareness compared to developed markets, and varying access to advanced reproductive technologies across the region.

RESEARCH METHODOLOGY

This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

Secondary Research

Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

Data Triangulation

After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

Market Definition

Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

Preimplantation genetic screening for abnormal chromosome number (PGT-A)
Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

Stakeholders

Contract research organizations (CROs)
Contract development and manufacturing organizations (CDMOs)
In vitro fertilization (IVF) centers and fertility clinics
Life science companies
Fertility clinics
Academic & research institutes
Private research institutes
Venture capitalists & investors
Market research & consulting firms
Government associations
Medical institutions & universities
Hospitals & clinics

Report Objectives

To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

Get the Full Preimplantation Genetic Testing Market Report

Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

Download Sample Pages Buy Report

REPORT COVERAGE

＋

Report Description
Market Overview
Market Dynamics
Related Ecosystem
Key Takeaways
Market Scope
Report Segmentation
Target Audience
Key Companies

Market Size in	USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered	Value (USD MN)